China's SFDA grants production license to TPI anti-diabetic drug Gliclazide

Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced TPI has received the production license for its anti-diabetic drug Gliclazide Tablets (80 mg formulation) from China's State Food and Drug Administration (SFDA). The national pharmaceutical certificate number for TPI's new Gliclazide Tablets is also issued: H20113233.

Gliclazide is an oral anti-diabetic drug used for the control of hyperglycemia in gliclazide-response diabetes mellitus of stable, mild, non-ketosis prone, maturity-onset. It is used when proper dietary adjustment and exercise fail to reduce the blood sugar content or for conditions that are not suitable for insulin therapy.

Gliclazide is listed in the National Medical Reimbursement List (NMRL) of China. The approval and production license issuance brought TPI's portfolio to 58 products in total, 24 of which are reimbursed by China's Government Medical Insurance Program.